Adil Daud, MD

Oncologist and melanoma specialist

Dr. Adil Daud, an oncologist, is co-director of the Melanoma Center and a specialist in melanoma and other skin cancers. In addition to caring for patients, he directs melanoma research to better understand the biology of melanoma and to develop new treatments for the disease. Daud has developed and led many clinical trials that have expanded the use of gene therapy for melanoma.

Daud earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Fla. for seven years. Daud has won numerous awards, including the American Society for Clinical Oncology's Young Investigator award and Castle Connolly's Best Doctors in America award. He is a professor of hematology-oncology at UCSF.

Clinics

Melanoma and Skin Cancer Program
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-9900
Fax: (415) 885-3802

Hours: Monday to Friday, 8 a.m. - 5 p.m.

Conditions & Treatments

Board Certification

Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine

Academic Title

Professor

More about Adil Daud

Additional Languages

Hindi

Education

Government Medical College, Nagpur 1986

Residencies

Indiana University School of Medicine 1997

Fellowships

Memorial Sloan-Kettering Cancer Center 2000

Selected Research and Publications

  1. Xu MJ, Wu S, Daud AI, Yu SS, Yom SS. In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. J Immunother Cancer. 2018 May 30; 6(1):43.
  2. Joseph RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud AI, Dronca RS, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone AM, Zhang J, Kang SP, Ebbinghaus SW, Anderson KM, Gangadhar T. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab. Clin Cancer Res. 2018 Apr 23.
  3. Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother. 2018 Mar 01; 1-5.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.